<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7344049\results\search\disease\results.xml">
  <result pre="stated in a credit line to the data. Abstract Coronavirus" exact="disease" post="(COVID-19) caused by severe acute respiratory syndrome coronavirus 2"/>
  <result pre="to the data. Abstract Coronavirus disease (COVID-19) caused by severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) recently was declared a"/>
  <result pre="the data. Abstract Coronavirus disease (COVID-19) caused by severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) recently was declared a pandemic"/>
  <result pre="data. Abstract Coronavirus disease (COVID-19) caused by severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) recently was declared a pandemic by"/>
  <result pre="common cold symptoms while two other strain including Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) reported in the Middle East in"/>
  <result pre="cold symptoms while two other strain including Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) reported in the Middle East in 2012"/>
  <result pre="reported in the Middle East in 2012 [2] and severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) observed in 2003 in Guangdong"/>
  <result pre="in the Middle East in 2012 [2] and severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) observed in 2003 in Guangdong Province,"/>
  <result pre="the Middle East in 2012 [2] and severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) observed in 2003 in Guangdong Province, China,"/>
  <result pre="of January 2020 as a novel coronavirus 2019. A first" exact="viral" post="genome sequence was issued on 10 January 2020 [5],"/>
  <result pre="confirmed the indicating association of the virus with the severe" exact="acute" post="respiratory syndrome (SARS) [6]. In the light of available"/>
  <result pre="the indicating association of the virus with the severe acute" exact="respiratory" post="syndrome (SARS) [6]. In the light of available evidence,"/>
  <result pre="indicating association of the virus with the severe acute respiratory" exact="syndrome" post="(SARS) [6]. In the light of available evidence, SARS-CoV-2"/>
  <result pre="the most possible from bats directly or maybe via other" exact="intermediate" post="animals, confirmation of clear source (s) will help to"/>
  <result pre="in a few Chinese restaurants and local markets. After the" exact="primary" post="transmission, the rapid rate of infection spread due to"/>
  <result pre="local markets. After the primary transmission, the rapid rate of" exact="infection" post="spread due to direct transmission from humans to humans"/>
  <result pre="symptoms of COVID-19 patients include dry cough, fatigue, fever, dyspnea" exact="runny nose," post="and in some cases nasal congestion but fever is"/>
  <result pre="a problem before proceeding to treatment. Initially, biochemical tests from" exact="respiratory" post="biological samples (bronchial aspirates, sputum, bronchoalveolar lavage fluid, nasal"/>
  <result pre="identify particular viruses including influenza, parainfluenza virus, MERS-CoV, SARS-CoV, adenovirus," exact="avian influenza" post="[11]. Molecular techniques in comparison with Biochemical tests are"/>
  <result pre="within the infected organism but are also important routes toward" exact="disease" post="prevention and treatment [13]. At the time of writing"/>
  <result pre="TableÂ 1 [14]. TableÂ 1 Therapeutic options for COVID-19 [59]" exact="Diseases" post="Drug targets Antiviral agents Status Target pathogens RefS. SARS-CoV-2;"/>
  <result pre="100] SARS-CoV-2; SARS-CoV; MERS-CoV Interferon response Recombinant interferons Approved Metastatic" exact="renal cell carcinoma" post="(IFN-Î±2a) [101â€&quot;103] Approved Melanoma (IFN-Î±2b) Approved Multiple sclerosis (IFN-Î²1a,"/>
  <result pre="SARS-CoV; MERS-CoV Interferon response Recombinant interferons Approved Metastatic renal cell" exact="carcinoma" post="(IFN-Î±2a) [101â€&quot;103] Approved Melanoma (IFN-Î±2b) Approved Multiple sclerosis (IFN-Î²1a,"/>
  <result pre="Recombinant interferons Approved Metastatic renal cell carcinoma (IFN-Î±2a) [101â€&quot;103] Approved" exact="Melanoma" post="(IFN-Î±2b) Approved Multiple sclerosis (IFN-Î²1a, 1b), chronic granulomatous disease"/>
  <result pre="Metastatic renal cell carcinoma (IFN-Î±2a) [101â€&quot;103] Approved Melanoma (IFN-Î±2b) Approved" exact="Multiple" post="sclerosis (IFN-Î²1a, 1b), chronic granulomatous disease (IFN-Î³) SARS-CoV-2; SARS-CoV;"/>
  <result pre="(IFN-Î±2a) [101â€&quot;103] Approved Melanoma (IFN-Î±2b) Approved Multiple sclerosis (IFN-Î²1a, 1b)," exact="chronic" post="granulomatous disease (IFN-Î³) SARS-CoV-2; SARS-CoV; MERS-CoV Endosomal acidification Chloroquine"/>
  <result pre="Approved Melanoma (IFN-Î±2b) Approved Multiple sclerosis (IFN-Î²1a, 1b), chronic granulomatous" exact="disease" post="(IFN-Î³) SARS-CoV-2; SARS-CoV; MERS-CoV Endosomal acidification Chloroquine Approved Malaria"/>
  <result pre="granulomatous disease (IFN-Î³) SARS-CoV-2; SARS-CoV; MERS-CoV Endosomal acidification Chloroquine Approved" exact="Malaria" post="and certain amoeba infections [99, 104â€&quot;106] Open-label trial SARS-CoV-2"/>
  <result pre="SARS-CoV; MERS-CoV Endosomal acidification Chloroquine Approved Malaria and certain amoeba" exact="infections" post="[99, 104â€&quot;106] Open-label trial SARS-CoV-2 Broad-spectrum(e.g. coronaviruses; SARS-CoV-2) Interferon"/>
  <result pre="Open-label trial SARS-CoV-2 Broad-spectrum(e.g. coronaviruses; SARS-CoV-2) Interferon response Nitazoxanide Approved" exact="Diarrhea" post="[99, 107] Broad-spectrum (HCoV-229E) Interferon response Cyclophilin inhibitors (Compound"/>
  <result pre="of using traditional Chinese medicines (TCM) against most of the" exact="viral" post="infections including large-scale cold outbreaks being effective since Zhong-Jin"/>
  <result pre="using traditional Chinese medicines (TCM) against most of the viral" exact="infections" post="including large-scale cold outbreaks being effective since Zhong-Jin Zhang"/>
  <result pre="process are shown in Fig.Â 1. Few examples relevant to" exact="respiratory" post="viral infections e.g. Yin-Qiao-San and Jing-Fang-Bai-Du-San dispelling wind and"/>
  <result pre="are shown in Fig.Â 1. Few examples relevant to respiratory" exact="viral" post="infections e.g. Yin-Qiao-San and Jing-Fang-Bai-Du-San dispelling wind and cold,"/>
  <result pre="shown in Fig.Â 1. Few examples relevant to respiratory viral" exact="infections" post="e.g. Yin-Qiao-San and Jing-Fang-Bai-Du-San dispelling wind and cold, Ma-Xing-Shi-Gan-Tang"/>
  <result pre="of traditional Chinese medicine, which are observed quite effective against" exact="viral" post="epidemics in past before effective vaccines were developed for"/>
  <result pre="epidemics in past before effective vaccines were developed for the" exact="complete" post="virus elimination so the implementation could be a hopeful"/>
  <result pre="early indications matching the molecular mechanisms and pathophysiology of the" exact="disease" post="[19]. TCM for viral infective treatments in clinics/antiviral components"/>
  <result pre="molecular mechanisms and pathophysiology of the disease [19]. TCM for" exact="viral" post="infective treatments in clinics/antiviral components in TCM TCM is"/>
  <result pre="mechanisms and pathophysiology of the disease [19]. TCM for viral" exact="infective" post="treatments in clinics/antiviral components in TCM TCM is composed"/>
  <result pre="virus [20]. Ginsenosides has a protective effect on the lethal" exact="infection" post="of a Hemagglutinating virus of Japan (HVJ), as well"/>
  <result pre="Japan (HVJ), as well as has antiviral activity on the" exact="hepatitis" post="A virus, coxsackievirus B3, enterovirus 71, and human rhinovirus"/>
  <result pre="enterovirus 71, and human rhinovirus 3 [21]. Ginsenoside Rg3 attenuates" exact="hepatitis" post="B virus DNA replication through the degradation of TRAF6/TAK1"/>
  <result pre="and the inhibition of JNK/AP-1 signaling [22], and Rg3 inhibits" exact="hepatitis C" post="virus (HCV) infection via restoring the HCV-induced dynamin-related protein"/>
  <result pre="JNK/AP-1 signaling [22], and Rg3 inhibits hepatitis C virus (HCV)" exact="infection" post="via restoring the HCV-induced dynamin-related protein 1-mediated aberrant mitochondrial"/>
  <result pre="1-mediated aberrant mitochondrial dynamics [23]. Glycyrrhizic acid is effective against" exact="infection" post="of coxsackievirus A16 and enterovirus 71 while Glycyrrhizin has"/>
  <result pre="the replication of the SARS-associated virus [24]. Radix Glycyrrhizae restricts" exact="infection" post="of the human respiratory syncytial virus through preventing viral"/>
  <result pre="SARS-associated virus [24]. Radix Glycyrrhizae restricts infection of the human" exact="respiratory" post="syncytial virus through preventing viral attachment, internalization, and by"/>
  <result pre="restricts infection of the human respiratory syncytial virus through preventing" exact="viral" post="attachment, internalization, and by stimulating the secretion of IFN"/>
  <result pre="including quercetin and isoquercetin. Houttuynia cordata Thunb (HCT) blocks HSV" exact="infection" post="through inhibition of NF-ÎºB activation [26]. HCT water extract"/>
  <result pre="the secretion of IL-2 and IL-10 [27]. HCT alleviatesÂ H1N1-induced" exact="acute" post="lung injury in mice by inhibition of influenza neuraminidase"/>
  <result pre="modulating NS1-mediated cellular innate immune responses [28]. Baicalein triazole inhibits" exact="respiratory" post="syncytial virus (RSV) -infection and prevents pulmonary airway inflammation"/>
  <result pre="Baicalein triazole inhibits respiratory syncytial virus (RSV) -infection and prevents" exact="pulmonary" post="airway inflammation through the activation of the IFN signaling"/>
  <result pre="been emphasized in the â€œDiagnosis and treatment of novel Coronavirus" exact="Pneumonia" post="(Trail Version 6)â€�, and some Chinese patent medicines are"/>
  <result pre="function to reduce inflammation and oxidative stress damage, and inhibit" exact="pulmonary" post="fibrosis. XBJI significantly improves the primary endpoint of the"/>
  <result pre="stress damage, and inhibit pulmonary fibrosis. XBJI significantly improves the" exact="primary" post="endpoint of the pneumonia severity index in critically ill"/>
  <result pre="pulmonary fibrosis. XBJI significantly improves the primary endpoint of the" exact="pneumonia" post="severity index in critically ill patients with severe community-acquired"/>
  <result pre="pneumonia severity index in critically ill patients with severe community-acquired" exact="pneumonia" post="[32]. Xiyanping injection (Approval ID: 2010-03, XYPI), the major"/>
  <result pre="bioactive ingredient is sulfonated andrographolide, has a significant effect on" exact="acute" post="viral infection of the respiratory system, foot and mouth"/>
  <result pre="ingredient is sulfonated andrographolide, has a significant effect on acute" exact="viral infection" post="of the respiratory system, foot and mouth disease, mycoplasmal"/>
  <result pre="is sulfonated andrographolide, has a significant effect on acute viral" exact="infection" post="of the respiratory system, foot and mouth disease, mycoplasmal"/>
  <result pre="has a significant effect on acute viral infection of the" exact="respiratory" post="system, foot and mouth disease, mycoplasmal pneumonia in children"/>
  <result pre="viral infection of the respiratory system, foot and mouth disease," exact="mycoplasmal pneumonia" post="in children [33]. Shenfu injection (SFI) reduces the levels"/>
  <result pre="infection of the respiratory system, foot and mouth disease, mycoplasmal" exact="pneumonia" post="in children [33]. Shenfu injection (SFI) reduces the levels"/>
  <result pre="cytokines levels [34]. A study has shown that SFI alleviates" exact="acute" post="lung injury and improves the survival rate by suppressing"/>
  <result pre="[35]. Xingnaojing injection (XNJI), flavonoids are its main components, improves" exact="cerebral" post="ischemia/reperfusion injury through inhibiting the inflammatory response by the"/>
  <result pre="dangerous condition known as â€œcytokine stormâ€�, that is associated with" exact="disease" post="severity [37]. Clinical studies show that the levels of"/>
  <result pre="increased in severe or critical patients with COVID-19, while SARS-CoV-2" exact="infection" post="also increases secretion of anti-inflammatory cytokines (IL4 and IL10)"/>
  <result pre="replication and enhance complications related to severe cases of the" exact="disease" post="[39]. In patients having COVID-19, the levels of chemokines"/>
  <result pre="levels of chemokines and cytokines are noted abnormal which includes" exact="vascular" post="epithelial growth factor (VEGF), hepatocyte growth factor (HGF), TNF-Î±,"/>
  <result pre="of chemokines and cytokines are noted abnormal which includes vascular" exact="epithelial" post="growth factor (VEGF), hepatocyte growth factor (HGF), TNF-Î±, MIP"/>
  <result pre="the expression of interferon-stimulated genes (ISGs) for defense against numerous" exact="viral" post="infections. IFNs have been classified into three major subfamilies:"/>
  <result pre="viral infections. IFNs have been classified into three major subfamilies:" exact="type I" post="IFNs (comprising mainly IFN-Î± and IFN-Î²), type II IFNs"/>
  <result pre="major subfamilies: type I IFNs (comprising mainly IFN-Î± and IFN-Î²)," exact="type II" post="IFNs (IFN-Î³), and the recently identified type III IFNs"/>
  <result pre="and IFN-Î²), type II IFNs (IFN-Î³), and the recently identified" exact="type III" post="IFNs (IFN-Î»). Type I interferons(T1-IFN)have immune defense effect on"/>
  <result pre="IFNs (IFN-Î³), and the recently identified type III IFNs (IFN-Î»)." exact="Type I" post="interferons(T1-IFN)have immune defense effect on many viral infections [41]"/>
  <result pre="IFNs (IFN-Î»). Type I interferons(T1-IFN)have immune defense effect on many" exact="viral" post="infections [41] and are a critical effector of the"/>
  <result pre="(IFN-Î»). Type I interferons(T1-IFN)have immune defense effect on many viral" exact="infections" post="[41] and are a critical effector of the innate"/>
  <result pre="are a critical effector of the innate immune response following" exact="virus infection." post="IFN-Î±/Î² is a pluripotent inflammatory cytokine typically induced by"/>
  <result pre="infection. IFN-Î±/Î² is a pluripotent inflammatory cytokine typically induced by" exact="viral" post="infections. IFN-Î± is produced by leukocytes while IFN-Î² is"/>
  <result pre="mediated Beclin-1 (BECN1) ISGylation and autophagy inhibition [42]. IFN-Î± inhibits" exact="acute" post="IAV replication and controls the excessive immunopathology caused by"/>
  <result pre="showed that IFN-Î± and IFN-Î² both have protective effects during" exact="acute" post="chikungunya virus (CHIKV) infection, but the mechanisms are different."/>
  <result pre="that IFN-Î± and IFN-Î² both have protective effects during acute" exact="chikungunya" post="virus (CHIKV) infection, but the mechanisms are different. IFN-Î±"/>
  <result pre="pathogenesis by alleviating inflammation induced by neutrophils [43]. IFN-Î³, as" exact="type II" post="interferons are released by activated T cells, natural killer"/>
  <result pre="innate and adaptive immunity. IFN-Î³ is a hallmark cytokine of" exact="type I" post="helper T cells (Th1 cells), which have antivirus, immune"/>
  <result pre="(Th1 cells), which have antivirus, immune regulation, and antitumor properties." exact="Type III" post="IFN or IFN-Î» is mainly as an epithelial cytokine,"/>
  <result pre="properties. Type III IFN or IFN-Î» is mainly as an" exact="epithelial" post="cytokine, which inhibits viral replication in epithelial cells and"/>
  <result pre="or IFN-Î» is mainly as an epithelial cytokine, which inhibits" exact="viral" post="replication in epithelial cells and has a protective effect"/>
  <result pre="mainly as an epithelial cytokine, which inhibits viral replication in" exact="epithelial" post="cells and has a protective effect on mucosal sites"/>
  <result pre="viruses and is a potent innate immune regulator of intestinal" exact="viral" post="infections, such as rotavirus, reovirus, norovirus, enterovirus, parvovirus, and"/>
  <result pre="with IFNÎ± [46]. IFN-Î» also suppresses the replication of severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) in both lung and gastrointestinal"/>
  <result pre="IFNÎ± [46]. IFN-Î» also suppresses the replication of severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) in both lung and gastrointestinal tracts."/>
  <result pre="[46]. IFN-Î» also suppresses the replication of severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) in both lung and gastrointestinal tracts. IFN-Î»3"/>
  <result pre="many patients do not tolerate chimeric antibodies because of the" exact="hypersensitivity" post="reactions to the agents which are non-human components. There"/>
  <result pre="another issue regarding immunosuppression which results in increasing the microorganismsâ€™" exact="infections" post="so in patients the latent infections may reactivate such"/>
  <result pre="in increasing the microorganismsâ€™ infections so in patients the latent" exact="infections" post="may reactivate such as tuberculosis, Hepatitis B and Pnuemocystis"/>
  <result pre="in patients the latent infections may reactivate such as tuberculosis," exact="Hepatitis" post="B and Pnuemocystis pneumonia. As these agents should be"/>
  <result pre="of the site of injection [48]. Role of interleukin in" exact="virus infection" post="Interleukin is a family of cytokines with bidirectional immune-modulatory"/>
  <result pre="the site of injection [48]. Role of interleukin in virus" exact="infection" post="Interleukin is a family of cytokines with bidirectional immune-modulatory"/>
  <result pre="antigen-specific adaptive immunity [49]. IL-12 plays a crucial role in" exact="type 1" post="immunity, which induces many cytokines and inflammatory responses. IL-12"/>
  <result pre="IL-12 has a protective effect and increases the resistance to" exact="infection" post="in herpes simplex virus type 1(HSV-1)-thermally injured mice. IL-12"/>
  <result pre="a protective effect and increases the resistance to infection in" exact="herpes" post="simplex virus type 1(HSV-1)-thermally injured mice. IL-12 could down-regulate"/>
  <result pre="PD-1 and increase CD8 functionality for immunity in persistent HBV" exact="infections" post="[50]. IL-23 is a pro-inflammatory cytokine as well as"/>
  <result pre="IFN-Î± responsiveness to promote HCV eradication. IL-23 promotes host resistance" exact="vaccinia" post="virus infection via the IL-23/IL-17 axis. IL-23 produced by"/>
  <result pre="responsiveness to promote HCV eradication. IL-23 promotes host resistance vaccinia" exact="virus infection" post="via the IL-23/IL-17 axis. IL-23 produced by myeloid dendritic"/>
  <result pre="to promote HCV eradication. IL-23 promotes host resistance vaccinia virus" exact="infection" post="via the IL-23/IL-17 axis. IL-23 produced by myeloid dendritic"/>
  <result pre="cells induces SOCS1 expression and causes T cell dysfunction during" exact="HIV infection" post="[51]. IL-27 is secreted by antigen-presenting cells such as"/>
  <result pre="induces SOCS1 expression and causes T cell dysfunction during HIV" exact="infection" post="[51]. IL-27 is secreted by antigen-presenting cells such as"/>
  <result pre="[53]. IL-27 has broad anti-viral effects, such as HIV-1, HCV," exact="herpes" post="simplex virus type 1 (HSV-1), and HBV, but the"/>
  <result pre="broad anti-viral effects, such as HIV-1, HCV, herpes simplex virus" exact="type 1" post="(HSV-1), and HBV, but the mechanism differs. IL-27 could"/>
  <result pre="but the mechanism differs. IL-27 could prevent macrophages from HIV-1" exact="infection" post="by down-regulating spectrin Î² none-erythrocyte 1 (SPTBN1). IL-27 is"/>
  <result pre="the activation of STAT-1 and it can also control HSV-1" exact="infection" post="via the up-regulation of STAT-1, IL-6, and IP-10 and"/>
  <result pre="plays an important role in the immune tolerance period of" exact="viral infection." post="IL-35 induces immune-tolerance through suppressing pro-inflammatory cytokine expression during"/>
  <result pre="infection. IL-35 induces immune-tolerance through suppressing pro-inflammatory cytokine expression during" exact="chronic" post="HBV infection [55]. IL-35 contributes to prevent HCV-induced liver"/>
  <result pre="induces immune-tolerance through suppressing pro-inflammatory cytokine expression during chronic HBV" exact="infection" post="[55]. IL-35 contributes to prevent HCV-induced liver damage via"/>
  <result pre="inflammatory responses, while play a contradictory role in persistent HCV" exact="infection" post="by the inhibition of antiviral immune activity. IL-35 is"/>
  <result pre="of antiviral immune activity. IL-35 is the high expression in" exact="peripheral" post="blood mononuclear cells and throat swabs of patients with"/>
  <result pre="patients with seasonal IAV, which inhibits IAV RNA replication and" exact="viral" post="protein synthesis by induction of type I and III"/>
  <result pre="IAV RNA replication and viral protein synthesis by induction of" exact="type I" post="and III IFN [56]. Overall, IL-35 plays a critical"/>
  <result pre="[56]. Overall, IL-35 plays a critical role in inflammatory and" exact="autoimmune diseases," post="but the functions of IL-35 in antiviral infections are"/>
  <result pre="and autoimmune diseases, but the functions of IL-35 in antiviral" exact="infections" post="are not yet well understood. IL-15 is critical for"/>
  <result pre="secretion of IFN. Therefore, IL-15 potentially stimulates NK cells from" exact="HIV-positive" post="donors and improves NK cellsâ€™Â antiviral effects to clear"/>
  <result pre="their activity to control HIV [58]. IL-15 is up-regulated during" exact="primary" post="human immunodeficiency virus (HIV) infection, which renders primary human"/>
  <result pre="to control HIV [58]. IL-15 is up-regulated during primary human" exact="immunodeficiency" post="virus (HIV) infection, which renders primary human CD4+ cells"/>
  <result pre="up-regulated during primary human immunodeficiency virus (HIV) infection, which renders" exact="primary" post="human CD4+ cells more susceptible to HIV. IL-15 and"/>
  <result pre="virus, dengue virus, and HSV-2 [60]. IL-22 induces the proliferation" exact="of liver" post="stem/progenitor cells via activating STAT3 and reduces pathology in"/>
  <result pre="activating STAT3 and reduces pathology in mice and patients with" exact="chronic" post="HBV infection. IL-22 could enhance the expression of the"/>
  <result pre="rotavirus replication by cooperating with IFN-Î» [61]. After the influenza" exact="virus infection," post="IL-22 promotes epithelial cell regeneration, while prevents lung inflammation"/>
  <result pre="with IFN-Î» [61]. After the influenza virus infection, IL-22 promotes" exact="epithelial" post="cell regeneration, while prevents lung inflammation and secondary bacterial"/>
  <result pre="influenza virus infection, IL-22 promotes epithelial cell regeneration, while prevents" exact="lung inflammation" post="and secondary bacterial infection. IL-22 could reduce the secretion"/>
  <result pre="IL-22 promotes epithelial cell regeneration, while prevents lung inflammation and" exact="secondary" post="bacterial infection. IL-22 could reduce the secretion of pro-inflammatory"/>
  <result pre="promotes epithelial cell regeneration, while prevents lung inflammation and secondary" exact="bacterial infection." post="IL-22 could reduce the secretion of pro-inflammatory cytokines and"/>
  <result pre="accessory proteins. Some of these enzymes are responsible for the" exact="viral" post="life cycle and attachment to host cells for penetration."/>
  <result pre="has the affinity to inhibit AAK1, thus could prevent COVID-19" exact="acute" post="respiratory disease by reducing virus entry and inflammation [65]."/>
  <result pre="the affinity to inhibit AAK1, thus could prevent COVID-19 acute" exact="respiratory" post="disease by reducing virus entry and inflammation [65]. Host"/>
  <result pre="affinity to inhibit AAK1, thus could prevent COVID-19 acute respiratory" exact="disease" post="by reducing virus entry and inflammation [65]. Host Kinases"/>
  <result pre="cascades regulating the expression of cytokines and chemokines resulting in" exact="infection" post="prevention. Another type of kinases involves c-Jun N-terminal kinases"/>
  <result pre="6 (IL-6), TNF-Î± and interferon Î² (IFN-Î²) [66]. Similarly, upon" exact="viral infection" post="early cytokines dysregulation is an outcome of high pathogenesis,"/>
  <result pre="(IL-6), TNF-Î± and interferon Î² (IFN-Î²) [66]. Similarly, upon viral" exact="infection" post="early cytokines dysregulation is an outcome of high pathogenesis,"/>
  <result pre="is inhibited by paroxetine acting as virion un-coating can reduce" exact="viral" post="load in respiratory tracts but is not helpful in"/>
  <result pre="paroxetine acting as virion un-coating can reduce viral load in" exact="respiratory" post="tracts but is not helpful in lethal infection prevention"/>
  <result pre="load in respiratory tracts but is not helpful in lethal" exact="infection" post="prevention [68]. In another study treatment of mice with"/>
  <result pre="key biological molecules of the immune system, effective in minimizing" exact="viral" post="pathogenesis because of their specificity to host protein. Monoclonal"/>
  <result pre="to bind ACE2 of the host cell receptor and facilitate" exact="viral" post="entry. By targeting TSP effective neutralizing antibodies could be"/>
  <result pre="targeting TSP effective neutralizing antibodies could be effective to inhibit" exact="viral" post="attachment to host cells. CR3022 is a SARS-CoV-specific human"/>
  <result pre="some required modification could be helpful in antibodies development for" exact="complete" post="neutralization of SARS-CoV-2 in human. There are some limitations"/>
  <result pre="peptides have a strong potential as a therapeutic drug for" exact="infection" post="prevention. A single peptide can be verified for broad-spectrum"/>
  <result pre="cationic peptide is Î±-defensin having antiviral activity against cytomegalovirus and" exact="herpes" post="simplex virus, while human neutrophil peptide 1 (HNP1)Â with"/>
  <result pre="1 (HNP1)Â with the in vitroÂ significant effects against vesicular" exact="stomatitis" post="virus. Due to high viral mutation probability traditional vaccines"/>
  <result pre="vitroÂ significant effects against vesicular stomatitis virus. Due to high" exact="viral" post="mutation probability traditional vaccines are limited in certain epidemics,"/>
  <result pre="virus. Due to high viral mutation probability traditional vaccines are" exact="limited" post="in certain epidemics, in such scenario vaccination strategies based"/>
  <result pre="such scenario vaccination strategies based on antibody-mediated protection can stop" exact="virus infection," post="but high mutation rates make escape virus for host"/>
  <result pre="aspects like entry blocker peptide helps in the prevention of" exact="viral" post="fusion to host cells, virucidal peptides act upon virus"/>
  <result pre="peptides act upon virus envelope, and disrupt the structure and" exact="viral" post="replication inhibitors can block further division [76]. A major"/>
  <result pre="responses can be targeted by these approaches [79]. After the" exact="complete" post="structural and molecular composition is fully explored, several pre-existing"/>
  <result pre="in reducing cytokines/chemokines levels and mortality in mice but due" exact="limited" post="existing knowledge in present, these are not recommended in"/>
  <result pre="existing knowledge in present, these are not recommended in severe" exact="respiratory" post="viral infections caused by SARS-CoV-2 [80]. On the hand"/>
  <result pre="knowledge in present, these are not recommended in severe respiratory" exact="viral" post="infections caused by SARS-CoV-2 [80]. On the hand Corticosteroids"/>
  <result pre="in present, these are not recommended in severe respiratory viral" exact="infections" post="caused by SARS-CoV-2 [80]. On the hand Corticosteroids are"/>
  <result pre="in 2009 resulting in treatment of 40% infected individuals having" exact="acute" post="respiratory distress syndrome in France while 62.2% H7N9 avian"/>
  <result pre="2009 resulting in treatment of 40% infected individuals having acute" exact="respiratory" post="distress syndrome in France while 62.2% H7N9 avian influenza-infected"/>
  <result pre="in treatment of 40% infected individuals having acute respiratory distress" exact="syndrome" post="in France while 62.2% H7N9 avian influenza-infected patients were"/>
  <result pre="to inflammation, in such patients corticosteroids were used frequently for" exact="viral" post="clearance but have found to be not significantly effective"/>
  <result pre="[11]. Reactive oxygen species (ROS) also have a role in" exact="viral" post="replication and inflammatory responses thus antioxidants having anti-inflammatory and"/>
  <result pre="be also tested to treat cytokine storm. Antioxidants monotherapy has" exact="limited" post="effects on cytokine storm so the combination with antiviral"/>
  <result pre="II in SARS-CoV-2 patients is related with lung injury and" exact="viral" post="pathogenesis, so several angiotensin receptor blockers could have potential"/>
  <result pre="viruses. Statin in combination with caffeine is more effective in" exact="viral" post="replication inhibition and alleviation of lung injury and has"/>
  <result pre="(CD134) can play a major role in T-cell-mediated immunotherapy against" exact="viral infection" post="in the lungs through up-regulating anti-apoptotic gene expression [86]."/>
  <result pre="can play a major role in T-cell-mediated immunotherapy against viral" exact="infection" post="in the lungs through up-regulating anti-apoptotic gene expression [86]."/>
  <result pre="also possess immune-modulatory properties and anti-inflammatory activities e.g. Macrolides reduced" exact="viral" post="replication and reduced inflammatory cell number [87]. Arbidol is"/>
  <result pre="which might also be effective in the treatment of severe" exact="viral infection" post="and reducing inflammation by modulating the expression of pro-inflammatory"/>
  <result pre="might also be effective in the treatment of severe viral" exact="infection" post="and reducing inflammation by modulating the expression of pro-inflammatory"/>
  <result pre="extracts from Jiawei-Yupingfeng-Tang can also have a big contribution against" exact="viral infection" post="by modulating immune effects and can alleviate viral-induced lung"/>
  <result pre="from Jiawei-Yupingfeng-Tang can also have a big contribution against viral" exact="infection" post="by modulating immune effects and can alleviate viral-induced lung"/>
  <result pre="broad immune-modulatory effect and is used for adjuvant treatment of" exact="malignant" post="tumors in clinical. Studies have demonstrated that PA-MSHA promotes"/>
  <result pre="pathway and improves HIV-1 DNA vaccine immune response [90]. SARS-COV-2" exact="infection" post="in severe and critical stage can cause viral sepsis."/>
  <result pre="[90]. SARS-COV-2 infection in severe and critical stage can cause" exact="viral" post="sepsis. In addition, PA-MSHA effectively inhibits the release of"/>
  <result pre="inflammatory response and tissue injury, and lowers the rate of" exact="infection" post="complications in sepsis. PA-MSHA also can reverse the drug"/>
  <result pre="health and economic sectors. In past, two such epidemics of" exact="respiratory" post="complications were observed with the other two strains of"/>
  <result pre="mainly focused on quarantine affected individuals; restrict travelers from epicenters," exact="disease" post="control measures, transmission, and prevention to overcome further mortality"/>
  <result pre="and prevention to overcome further mortality until the development of" exact="complete" post="effective medications for COVID-19. No doubt these are effective"/>
  <result pre="medications for COVID-19. No doubt these are effective ways in" exact="disease" post="management, but this is not a long term possible"/>
  <result pre="can effectively decrease the duration of the virus in the" exact="upper" post="respiratory tract and also decrease the duration of the"/>
  <result pre="effectively decrease the duration of the virus in the upper" exact="respiratory" post="tract and also decrease the duration of the high"/>
  <result pre="antibodies [95]. In the current outbreak convalescent plasma therapy in" exact="uncontrolled" post="studies in China indeed indicated a beneficial treatment for"/>
  <result pre="ongoing COVID-19 outbreak. Abbreviations TCM Traditional Chinese medicine COVID Coronavirus" exact="disease" post="WHO World health organization MLCK Myosin light-chain kinase TLR"/>
  <result pre="2.ZakiAMVan BoheemenSBestebroerTMOsterhausADFouchierRAIsolation of a novel coronavirus from a man with" exact="pneumonia" post="in Saudi ArabiaN Engl J Med2012367191814182023075143 3.SuSWongGShiWLiuJLaiACZhouJet al.Epidemiology, genetic"/>
  <result pre="al.Epidemiology, genetic recombination, and pathogenesis of coronavirusesTrends Microbiol201624649050227012512 4.WHO. Coronavirus" exact="disease" post="(COVID-2019) situation reports, https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports; 2020. 5.Zhang Y-Z. Novel 2019"/>
  <result pre="Medical Soc; 2020. 8.WangNLiS-YYangX-LHuangH-MZhangY-JGuoHet al.Serological evidence of bat SARS-related coronavirus" exact="infection" post="in humans, ChinaVirol Sinica2018331104107 9.HongKong. Centre for Health Protection,"/>
  <result pre="ChinaVirol Sinica2018331104107 9.HongKong. Centre for Health Protection, Department of Healthâ€&quot;Severe" exact="Respiratory" post="Disease associated with a Novel Infectious Agent. 2020. https://www.chp.gov.hk/en/features/102465.html."/>
  <result pre="Sinica2018331104107 9.HongKong. Centre for Health Protection, Department of Healthâ€&quot;Severe Respiratory" exact="Disease" post="associated with a Novel Infectious Agent. 2020. https://www.chp.gov.hk/en/features/102465.html. 10.JinY-HCaiLChengZ-SChengHDengTFanY-Pet"/>
  <result pre="Protection, Department of Healthâ€&quot;Severe Respiratory Disease associated with a Novel" exact="Infectious" post="Agent. 2020. https://www.chp.gov.hk/en/features/102465.html. 10.JinY-HCaiLChengZ-SChengHDengTFanY-Pet al.A rapid advice guideline for"/>
  <result pre="the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected" exact="pneumonia" post="(standard version)Milit Med Res2020714 11.HuangCWangYLiXRenLZhaoJHuYet al.Clinical features of patients"/>
  <result pre="mNGS approach identifies a novel human coronavirus from two individual" exact="pneumonia" post="cases in 2019 Wuhan outbreakEmerg Microbes Infect20209131331932020836 13.ShiMZhangY-ZHolmesECMeta-transcriptomics and"/>
  <result pre="of traditional Chinese medical herbs in prevention and treatment of" exact="respiratory" post="syncytial virus. Evidence-Based Complementary and Alternative Medicine 2016;2016. 19.EngYSLeeCHLeeWCHuangCCChangJSUnraveling"/>
  <result pre="19.EngYSLeeCHLeeWCHuangCCChangJSUnraveling the molecular mechanism of traditional chinese medicine: formulas against" exact="acute" post="airway viral infections as examplesMolecules201924193505 20.PuXRenJMaXLiuLYuSLiXet al.Polyphylla saponin I"/>
  <result pre="molecular mechanism of traditional chinese medicine: formulas against acute airway" exact="viral" post="infections as examplesMolecules201924193505 20.PuXRenJMaXLiuLYuSLiXet al.Polyphylla saponin I has antiviral"/>
  <result pre="mechanism of traditional chinese medicine: formulas against acute airway viral" exact="infections" post="as examplesMolecules201924193505 20.PuXRenJMaXLiuLYuSLiXet al.Polyphylla saponin I has antiviral activity"/>
  <result pre="degradation and inhibition of JNK/AP-1 signalling by ginsenoside Rg3 attenuates" exact="hepatitis" post="B virus replicationInt J Biochem Cell Biol201345112612262124004833 23.KimSJJangJYKimEJChoEKAhnDGKimCet al.Ginsenoside"/>
  <result pre="virus replicationInt J Biochem Cell Biol201345112612262124004833 23.KimSJJangJYKimEJChoEKAhnDGKimCet al.Ginsenoside Rg3 restores" exact="hepatitis C" post="virusâ€&quot;induced aberrant mitochondrial dynamics and inhibits virus propagationHepatology201766375877128329914 24.CinatlJMorgensternBBauerGChandraPRabenauHDoerrHWGlycyrrhizin,"/>
  <result pre="YehCWangKCChiangLCShiehDEYenMHSanChang JWater extract of licorice had anti-viral activity against human" exact="respiratory" post="syncytial virus in human respiratory tract cell linesJ Ethnopharmacol2013148246647323643542"/>
  <result pre="had anti-viral activity against human respiratory syncytial virus in human" exact="respiratory" post="tract cell linesJ Ethnopharmacol2013148246647323643542 26.ChenXWangZYangZWangJXuYTanRXet al.Houttuynia cordata blocks HSV"/>
  <result pre="respiratory tract cell linesJ Ethnopharmacol2013148246647323643542 26.ChenXWangZYangZWangJXuYTanRXet al.Houttuynia cordata blocks HSV" exact="infection" post="through inhibition of NF-kappaB activationAntiviral Res201192234134521951655 27.LauKMLeeKMKoonCMCheungCSLauCPHoHMet al.Immunomodulatory and"/>
  <result pre="Antimicrob Chemother20146951298131024458510 29.YuWYLiLWuFZhangHHFangJZhongYSet al.Moslea Herba flavonoids alleviated influenza A virus-induced" exact="pulmonary" post="endothelial barrier disruption via suppressing NOX4/NF-kappaB/MLCK pathwayJ Ethnopharmacol202025311264132017949 30.LiCWangPZhangLLiMLeiXLiuSet"/>
  <result pre="on the effects and mechanism of xuebijing injection in severe" exact="pneumonia" post="patientsJ Tradit Chin Med2011311464921563507 32.SongYYaoCYaoYHanHZhaoXYuKet al.XueBiJing injection versus placebo"/>
  <result pre="controlled trialCrit Care Med2019479e735e74331162191 33.LiQLiZYZhangJGuoWNXuXMSunFXet al.Xiyanping Plus Azithromycin Chemotherapy in" exact="Pediatric" post="Patients with Mycoplasma pneumoniae Pneumonia: a Systematic Review and"/>
  <result pre="J Integr Med201622210110925253551 35.LiuXAiFLiHXuQMeiLMiaoJet al.Anti-Inflammatory Effects of Shenfu Injection against" exact="Acute" post="Lung Injury through Inhibiting HMGB1-NF-kappaB Pathway in a Rat"/>
  <result pre="Med20192019985768331781288 36.MaRMaXWenJWangJXieQChenNet al.Preclinical evidence and mechanism of Xingnaojing injection for" exact="cerebral" post="ischemia: a systematic review and meta-analysis of animal studiesEvid"/>
  <result pre="Alternat Med20182018962417530581490 37.WongCKLamCWWuAKIpWKLeeNLChanIHet al.Plasma inflammatory cytokines and chemokines in severe" exact="acute" post="respiratory syndromeClin Exp Immunol200413619510315030519 38.Zhu N, Zhang D, Wang"/>
  <result pre="Med20182018962417530581490 37.WongCKLamCWWuAKIpWKLeeNLChanIHet al.Plasma inflammatory cytokines and chemokines in severe acute" exact="respiratory" post="syndromeClin Exp Immunol200413619510315030519 38.Zhu N, Zhang D, Wang W,"/>
  <result pre="and Research Team (2020) A novel Coronavirus from patients with" exact="pneumonia" post="in China, 2019. N Engl J Med. 2020. 39.Blanco-Melo"/>
  <result pre="Med J. 2020. 41.van den BroekMFMullerUHuangSZinkernagelRMAguetMImmune defence in mice lacking" exact="type I" post="and/or type II interferon receptorsImmunol Rev19951485188825279 42.TeijaroJRType I interferons"/>
  <result pre="41.van den BroekMFMullerUHuangSZinkernagelRMAguetMImmune defence in mice lacking type I and/or" exact="type II" post="interferon receptorsImmunol Rev19951485188825279 42.TeijaroJRType I interferons in viral control"/>
  <result pre="and/or type II interferon receptorsImmunol Rev19951485188825279 42.TeijaroJRType I interferons in" exact="viral" post="control and immune regulationCurrent opinion in virology201616314026812607 43.CookLELockeMCYoungARMonteKHedbergMLShimakRMet al.Distinct"/>
  <result pre="43.CookLELockeMCYoungARMonteKHedbergMLShimakRMet al.Distinct roles of interferon alpha and beta in controlling" exact="chikungunya" post="virus replication and modulating neutrophil-mediated inflammationJ Virol2019941 44.MordsteinMNeugebauerEDittVJessenBRiegerTFalconeVet al.Lambda"/>
  <result pre="replication and modulating neutrophil-mediated inflammationJ Virol2019941 44.MordsteinMNeugebauerEDittVJessenBRiegerTFalconeVet al.Lambda interferon renders" exact="epithelial" post="cells of the respiratory and gastrointestinal tracts resistant to"/>
  <result pre="inflammationJ Virol2019941 44.MordsteinMNeugebauerEDittVJessenBRiegerTFalconeVet al.Lambda interferon renders epithelial cells of the" exact="respiratory" post="and gastrointestinal tracts resistant to viral infectionsJ Virol201084115670567720335250 45.LeeSBaldridgeMTInterferon-lambda:"/>
  <result pre="epithelial cells of the respiratory and gastrointestinal tracts resistant to" exact="viral" post="infectionsJ Virol201084115670567720335250 45.LeeSBaldridgeMTInterferon-lambda: a potent regulator of intestinal viral"/>
  <result pre="to viral infectionsJ Virol201084115670567720335250 45.LeeSBaldridgeMTInterferon-lambda: a potent regulator of intestinal" exact="viral" post="infectionsFront Immunol2017874928713375 46.DavidsonSMcCabeTMCrottaSGadHHHesselEMBeinkeSet al.IFNlambda is a potent anti-influenza therapeutic"/>
  <result pre="Med2016891099111227520969 47.RamosELPreclinical and clinical development of pegylated interferon-lambda 1 in" exact="chronic hepatitis" post="CJ Interferon Cytokine Res201030859159520645873 48.DipiroJTTalbertRLYeeGCMatzkeGRWellsBGPoseyLMPharmacotherapy: a pathophysiologic approach2014New YorkMcGraw-Hill"/>
  <result pre="47.RamosELPreclinical and clinical development of pegylated interferon-lambda 1 in chronic" exact="hepatitis" post="CJ Interferon Cytokine Res201030859159520645873 48.DipiroJTTalbertRLYeeGCMatzkeGRWellsBGPoseyLMPharmacotherapy: a pathophysiologic approach2014New YorkMcGraw-Hill"/>
  <result pre="between innate resistance and adaptive immunity with a role in" exact="infection" post="and acquired immunodeficiencyJ Clin Immunol19941431491617929692 50.SchurichAPallettLJLubowieckiMSinghHDGillUSKennedyPTet al.The third signal"/>
  <result pre="resistance and adaptive immunity with a role in infection and" exact="acquired" post="immunodeficiencyJ Clin Immunol19941431491617929692 50.SchurichAPallettLJLubowieckiMSinghHDGillUSKennedyPTet al.The third signal cytokine IL-12"/>
  <result pre="by myeloid dendritic cells contributes to T-cell dysfunction in HIV" exact="type 1" post="infection by inducing SOCS1 expressionJ Infect Dis2015211575576825234720 52.Aparicio-SiegmundSGarbersCThe biology"/>
  <result pre="dendritic cells contributes to T-cell dysfunction in HIV type 1" exact="infection" post="by inducing SOCS1 expressionJ Infect Dis2015211575576825234720 52.Aparicio-SiegmundSGarbersCThe biology of"/>
  <result pre="cytokine and receptor family in graft-vs-host diseaseFront Immunol20191098831139181 54.HeikkilaONygardasMPaavilainenHRyodiEHukkanenVInterleukin-27 inhibits" exact="herpes" post="simplex virus type 1 infection by activating STAT1 and"/>
  <result pre="family in graft-vs-host diseaseFront Immunol20191098831139181 54.HeikkilaONygardasMPaavilainenHRyodiEHukkanenVInterleukin-27 inhibits herpes simplex virus" exact="type 1" post="infection by activating STAT1 and 3, interleukin-6, and chemokines"/>
  <result pre="graft-vs-host diseaseFront Immunol20191098831139181 54.HeikkilaONygardasMPaavilainenHRyodiEHukkanenVInterleukin-27 inhibits herpes simplex virus type 1" exact="infection" post="by activating STAT1 and 3, interleukin-6, and chemokines IP-10"/>
  <result pre="MIGJ Interferon Cytokine Res2016361161762927617644 55.ShaoXMaJJiaSYangLWangWJinZInterleukin-35 suppresses antiviral immune response in" exact="chronic hepatitis" post="B virus infectionFront Cell Infect Microbiol2017747229181338 56.WangLZhuSXuGFengJHanTZhaoFet al.Gene expression"/>
  <result pre="Interferon Cytokine Res2016361161762927617644 55.ShaoXMaJJiaSYangLWangWJinZInterleukin-35 suppresses antiviral immune response in chronic" exact="hepatitis" post="B virus infectionFront Cell Infect Microbiol2017747229181338 56.WangLZhuSXuGFengJHanTZhaoFet al.Gene expression"/>
  <result pre="through the ERK pathway to inhibit HCV replication, independent of" exact="type I" post="IFN signalingCytokine201912415443929908921 60.XuXQLiuYZhangBLiuHShaoDDLiuJBet al.IL-22 suppresses HSV-2 replication in human"/>
  <result pre="IFN signalingCytokine201912415443929908921 60.XuXQLiuYZhangBLiuHShaoDDLiuJBet al.IL-22 suppresses HSV-2 replication in human cervical" exact="epithelial" post="cellsCytokine201912315477631344598 61.HernandezPPMahlakoivTYangISchwierzeckVNguyenNGuendelFet al.Interferon-lambda and interleukin 22 act synergistically for"/>
  <result pre="dengue infectionEur J Immunol20134361529154423505056 63.Gimeno BriasSStackGStaceyMARedwoodAJHumphreysIRThe role of IL-22 in" exact="viral" post="infections: paradigms and paradoxesFront Immunol2016721127303405 64.ZumlaAChanJFAzharEIHuiDSYuenK-YCoronavirusesâ€&quot;drug discovery and therapeutic"/>
  <result pre="Phelan A, et al. Baricitinib as potential treatment for 2019-nCoV" exact="acute" post="respiratory disease. Lancet 2020. 66.XieJZhangSHuYLiDCuiJXueJet al.Regulatory roles of c-jun"/>
  <result pre="A, et al. Baricitinib as potential treatment for 2019-nCoV acute" exact="respiratory" post="disease. Lancet 2020. 66.XieJZhangSHuYLiDCuiJXueJet al.Regulatory roles of c-jun in"/>
  <result pre="Dis.201418421224792488 67.BÃ¶rgelingYSchmolkeMViemannDNordhoffCRothJLudwigSInhibition of p38 mitogen-activated protein kinase impairs influenza virus-induced" exact="primary" post="and secondary host gene responses and protects mice from"/>
  <result pre="of p38 mitogen-activated protein kinase impairs influenza virus-induced primary and" exact="secondary" post="host gene responses and protects mice from lethal H5N1"/>
  <result pre="infectionJ Biol Chem20142891132724189062 68.YÃ¡ngÃ¼ezEHunzikerADobayMPYildizSSchadingSElshinaEet al.Phosphoproteomic-based kinase profiling early in influenza" exact="virus infection" post="identifies GRK2 as antiviral drug targetNat Commun20189111329317637 69.XiaCSeoY-JStudstillCJVijayanMWolfJJHahmBTransient inhibition"/>
  <result pre="Biol Chem20142891132724189062 68.YÃ¡ngÃ¼ezEHunzikerADobayMPYildizSSchadingSElshinaEet al.Phosphoproteomic-based kinase profiling early in influenza virus" exact="infection" post="identifies GRK2 as antiviral drug targetNat Commun20189111329317637 69.XiaCSeoY-JStudstillCJVijayanMWolfJJHahmBTransient inhibition"/>
  <result pre="miceAntiviral Res201815817117730125617 70.SalazarGZhangNFuTAnZAntibody therapies for the prevention and treatment of" exact="viral" post="infectionsNPJ Vaccin201721112 71.FukushiSFukumaAKurosuTWatanabeSShimojimaMShiratoKet al.Characterization of novel monoclonal antibodies against"/>
  <result pre="J Pharmacol2009157222023319459844 74.Rosendahl HuberSvan BeekJde JongeJLuytjesWvan BaarleDT cell responses to" exact="viral" post="infectionsâ€&quot;opportunities for peptide vaccinationFront Immunol2014517124795718 75.Bojin F, Gavriliuc O,"/>
  <result pre="the past: possible urgent prevention and treatment options for severe" exact="acute" post="respiratory infections caused by 2019â€�nCoV. Chembiochem. 2020. 78.HaggagYADoniaAAOsmanMAEl-GizawySAPeptides as"/>
  <result pre="past: possible urgent prevention and treatment options for severe acute" exact="respiratory" post="infections caused by 2019â€�nCoV. Chembiochem. 2020. 78.HaggagYADoniaAAOsmanMAEl-GizawySAPeptides as drug"/>
  <result pre="possible urgent prevention and treatment options for severe acute respiratory" exact="infections" post="caused by 2019â€�nCoV. Chembiochem. 2020. 78.HaggagYADoniaAAOsmanMAEl-GizawySAPeptides as drug candidates:"/>
  <result pre="candidates: limitations and recent development perspectivesBiomed J201813 79.KaufmannSHDorhoiAHotchkissRSBartenschlagerRHost-directed therapies for" exact="bacterial" post="and viral infectionsNat Rev Drug Discov20181713528935918 80.ArabiYMFowlerRHaydenFGCritical care management"/>
  <result pre="and recent development perspectivesBiomed J201813 79.KaufmannSHDorhoiAHotchkissRSBartenschlagerRHost-directed therapies for bacterial and" exact="viral" post="infectionsNat Rev Drug Discov20181713528935918 80.ArabiYMFowlerRHaydenFGCritical care management of adults"/>
  <result pre="Drug Discov20181713528935918 80.ArabiYMFowlerRHaydenFGCritical care management of adults with community-acquired severe" exact="respiratory" post="viral infectionIntens Care Med2020114 81.GaoH-NLuH-ZCaoBDuBShangHGanJ-Het al.Clinical findings in 111"/>
  <result pre="Discov20181713528935918 80.ArabiYMFowlerRHaydenFGCritical care management of adults with community-acquired severe respiratory" exact="viral" post="infectionIntens Care Med2020114 81.GaoH-NLuH-ZCaoBDuBShangHGanJ-Het al.Clinical findings in 111 cases"/>
  <result pre="al.Clinical and biochemical indexes from 2019-nCoV infected patients linked to" exact="viral" post="loads and lung injurySci China Life Sci.2020111 85.LiuZGuoZWangGZhangDHeHLiGet al.Evaluation"/>
  <result pre="safety of a statin/caffeine combination against H5N1, H3N2 and H1N1" exact="virus infection" post="in BALB/c miceEur J Pharm Sci200938321522319616097 86.HumphreysIRWalzlGEdwardsLRaeAHillSHussellTA critical role"/>
  <result pre="of a statin/caffeine combination against H5N1, H3N2 and H1N1 virus" exact="infection" post="in BALB/c miceEur J Pharm Sci200938321522319616097 86.HumphreysIRWalzlGEdwardsLRaeAHillSHussellTA critical role"/>
  <result pre="critical role for OX40 in T cellâ€&quot;mediated immunopathology during lung" exact="viral" post="infectionJ Exp Med200319881237124214568982 87.ZarogoulidisPPapanasNKioumisIChatzakiEMaltezosEZarogoulidisKMacrolides: from in vitro anti-inflammatory and"/>
  <result pre="in vitro anti-inflammatory and immunomodulatory properties to clinical practice in" exact="respiratory" post="diseasesEur J Clin Pharmacol201268547950322105373 88.Zhang J, Zhou L, Yang"/>
  <result pre="Chen X. Therapeutic and triage strategies for 2019 novel coronavirus" exact="disease" post="in fever clinics. Lancet Respir Med. 2020. 89.LiuQLuLHuaMXuYXiongHHouWet al.Jiawei-Yupingfeng-Tang,"/>
  <result pre="Respir Med. 2020. 89.LiuQLuLHuaMXuYXiongHHouWet al.Jiawei-Yupingfeng-Tang, a Chinese herbal formula, inhibits" exact="respiratory" post="viral infections in vitro and in vivoJ Ethnopharmacol2013150252152824051026 90.HouJLiuYLiuYShaoYThe"/>
  <result pre="Med. 2020. 89.LiuQLuLHuaMXuYXiongHHouWet al.Jiawei-Yupingfeng-Tang, a Chinese herbal formula, inhibits respiratory" exact="viral" post="infections in vitro and in vivoJ Ethnopharmacol2013150252152824051026 90.HouJLiuYLiuYShaoYThe MSHA"/>
  <result pre="2020. 89.LiuQLuLHuaMXuYXiongHHouWet al.Jiawei-Yupingfeng-Tang, a Chinese herbal formula, inhibits respiratory viral" exact="infections" post="in vitro and in vivoJ Ethnopharmacol2013150252152824051026 90.HouJLiuYLiuYShaoYThe MSHA strain"/>
  <result pre="OC-AE. 2020. 93.of XITd, the tCmaei, treatment of novel coronary" exact="pneumonia" post="t, propose tmatd, Chinese a-ppot, Medicine. 2020. 94.ZhouQChenVShannonCPWeiX-SXiangXWangXet al.Interferon-Î±2b"/>
  <result pre="Immunol202011106132574262 95.MulanguSDoddLEDaveyRTJrTshiani MbayaOProschanMMukadiDet al.A randomized, controlled trial of Ebola virus" exact="disease" post="therapeuticsN Engl J Med2019381242293230331774950 96.ShenCWangZZhaoFYangYLiJYuanJet al.Treatment of 5 critically"/>
  <result pre="spikeSci Adv.2019544580 98.ColemanCMSiskJMMingoRMNelsonEAWhiteJMFriemanMBAbelson kinase inhibitors are potent inhibitors of severe" exact="acute" post="respiratory syndrome coronavirus and middle east respiratory syndrome coronavirus"/>
  <result pre="Adv.2019544580 98.ColemanCMSiskJMMingoRMNelsonEAWhiteJMFriemanMBAbelson kinase inhibitors are potent inhibitors of severe acute" exact="respiratory" post="syndrome coronavirus and middle east respiratory syndrome coronavirus fusionJ"/>
  <result pre="98.ColemanCMSiskJMMingoRMNelsonEAWhiteJMFriemanMBAbelson kinase inhibitors are potent inhibitors of severe acute respiratory" exact="syndrome" post="coronavirus and middle east respiratory syndrome coronavirus fusionJ Virol201690198924893327466418"/>
  <result pre="inhibitors of severe acute respiratory syndrome coronavirus and middle east" exact="respiratory" post="syndrome coronavirus fusionJ Virol201690198924893327466418 99.Wang M, Cao R, Zhang"/>
  <result pre="of severe acute respiratory syndrome coronavirus and middle east respiratory" exact="syndrome" post="coronavirus fusionJ Virol201690198924893327466418 99.Wang M, Cao R, Zhang L,"/>
  <result pre="Res. 2020:1â€&quot;3. 100.ItoKYotsuyanagiHSugiyamaMYatsuhashiHKarinoYTakikawaYet al.Geographic distribution and characteristics of genotype A" exact="hepatitis" post="B virus infection in acute and chronic hepatitis B"/>
  <result pre="100.ItoKYotsuyanagiHSugiyamaMYatsuhashiHKarinoYTakikawaYet al.Geographic distribution and characteristics of genotype A hepatitis B" exact="virus infection" post="in acute and chronic hepatitis B patients in JapanJ"/>
  <result pre="al.Geographic distribution and characteristics of genotype A hepatitis B virus" exact="infection" post="in acute and chronic hepatitis B patients in JapanJ"/>
  <result pre="and characteristics of genotype A hepatitis B virus infection in" exact="acute" post="and chronic hepatitis B patients in JapanJ Gastroenterol Hepatol201631118018926110395"/>
  <result pre="of genotype A hepatitis B virus infection in acute and" exact="chronic hepatitis" post="B patients in JapanJ Gastroenterol Hepatol201631118018926110395 101.FalzaranoDDe WitERasmussenALFeldmannFOkumuraAScottDPet al.Treatment"/>
  <result pre="genotype A hepatitis B virus infection in acute and chronic" exact="hepatitis" post="B patients in JapanJ Gastroenterol Hepatol201631118018926110395 101.FalzaranoDDe WitERasmussenALFeldmannFOkumuraAScottDPet al.Treatment"/>
  <result pre="macaquesNat Med201319101313131724013700 102.ChanJFChanK-HKaoRYToKKZhengB-JLiCPet al.Broad-spectrum antivirals for the emerging Middle East" exact="respiratory" post="syndrome coronavirusJ Infect201367660661624096239 103.KimUJWonE-JKeeS-JJungS-IJangH-CCase report combination therapy with lopinavir/ritonavir,"/>
  <result pre="Med201319101313131724013700 102.ChanJFChanK-HKaoRYToKKZhengB-JLiCPet al.Broad-spectrum antivirals for the emerging Middle East respiratory" exact="syndrome" post="coronavirusJ Infect201367660661624096239 103.KimUJWonE-JKeeS-JJungS-IJangH-CCase report combination therapy with lopinavir/ritonavir, ribavirin"/>
  <result pre="combination therapy with lopinavir/ritonavir, ribavirin and interferon-Î± for Middle East" exact="respiratory" post="syndromeAntiviral Ther201621455459 104.de WildeAHJochmansDPosthumaCCZevenhoven-DobbeJCvan NieuwkoopSBestebroerTMet al.Screening of an FDA-approved"/>
  <result pre="FDA-approved compound library identifies four small-molecule inhibitors of Middle East" exact="respiratory" post="syndrome coronavirus replication in cell cultureAntimicrob Agents Chemother20145884875488424841269 105.MadridPBChopraSMangerIDGilfillanLKeepersTRShurtleffACet"/>
  <result pre="compound library identifies four small-molecule inhibitors of Middle East respiratory" exact="syndrome" post="coronavirus replication in cell cultureAntimicrob Agents Chemother20145884875488424841269 105.MadridPBChopraSMangerIDGilfillanLKeepersTRShurtleffACet al.A"/>
  <result pre="small-molecule cyclophilin inhibitors with potent antiviral activitiesNat Commun201671111 109.AgostiniMLAndresELSimsACGrahamRLSheahanTPLuXet al.Coronavirus" exact="susceptibility to" post="the antiviral remdesivir (GS-5734) is mediated by the viral"/>
  <result pre="susceptibility to the antiviral remdesivir (GS-5734) is mediated by the" exact="viral" post="polymerase and the proofreading exoribonucleaseMBio201892e00221e0031829511076 110.SheahanTPSimsACGrahamRLMenacheryVDGralinskiLECaseJBet al.Broad-spectrum antiviral GS-5734"/>
  <result pre="zoonotic coronavirusesSci Transl Med20179396 111.ArabiYMAlothmanABalkhyHHAl-DawoodAAlJohaniSAl HarbiSet al.Treatment of Middle East" exact="respiratory" post="syndrome with a combination of lopinavir-ritonavir and interferon-Î²1b (MIRACLE"/>
  <result pre="coronavirusesSci Transl Med20179396 111.ArabiYMAlothmanABalkhyHHAl-DawoodAAlJohaniSAl HarbiSet al.Treatment of Middle East respiratory" exact="syndrome" post="with a combination of lopinavir-ritonavir and interferon-Î²1b (MIRACLE trial):"/>
 </snippets>
</snippetsTree>
